Azathioprine and Pulmonary alveolar proteinosis - a phase IV clinical study of FDA data

Summary:

Pulmonary alveolar proteinosis is found among people who take Azathioprine, especially for people who are male, 60+ old.

The phase IV clinical study analyzes which people take Azathioprine and have Pulmonary alveolar proteinosis. It is created by eHealthMe based on reports of 58,922 people who have side effects when taking Azathioprine from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On May, 26, 2023

58,922 people reported to have side effects when taking Azathioprine.
Among them, 10 people (0.02%) have Pulmonary alveolar proteinosis.

What is Azathioprine?

Azathioprine has active ingredients of azathioprine sodium. It is often used in crohn's disease. eHealthMe is studying from 59,607 Azathioprine users for its effectiveness, alternative drugs and more.

What is Pulmonary alveolar proteinosis?

Pulmonary alveolar proteinosis (diffuse lung disease characterized by the accumulation of amorphous, periodic acid-schiff (pas)-positive lipoproteinaceous material) is found to be associated with 242 drugs and 146 conditions by eHealthMe.

Number of Azathioprine and Pulmonary alveolar proteinosis reports submitted per year:

Could Azathioprine cause Pulmonary alveolar proteinosis?

Gender of people who have Pulmonary alveolar proteinosis when taking Azathioprine *:

female: 0.0 %
male: 100 %

Age of people who have Pulmonary alveolar proteinosis when taking Azathioprine *:

Common drugs people take besides Azathioprine *:

Common side effects people have besides Pulmonary alveolar proteinosis *:

Interstitial Lung Disease: 3 people, 30.00%
Pancytopenia (medical condition in which there is a reduction in the number of red and white blood cells, as well as platelets): 3 people, 30.00%
Septic Shock (shock due to blood infection): 3 people, 30.00%
Cardiac Failure: 2 people, 20.00%
Heart Attack: 2 people, 20.00%
Viral Infection: 2 people, 20.00%
Myelodysplastic Syndrome (a group of conditions that occur when the blood-forming cells in the bone marrow are damaged): 2 people, 20.00%
Acute Respiratory Failure: 2 people, 20.00%
Peritoneal Haemorrhage (peritoneal bleeding): 2 people, 20.00%
Respiratory Disorder (respiratory disease): 2 people, 20.00%

Common conditions people have *:

Behcet's Syndrome (involves inflammation of the blood vessels): 3 people, 30.00%
Histiocytosis Haematophagic: 2 people, 20.00%

* Approximation only. Some reports may have incomplete information.

Do you take Azathioprine and have Pulmonary alveolar proteinosis?

Check whether Pulmonary alveolar proteinosis is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related studies

How severe was Pulmonary alveolar proteinosis and when was it recovered:

Pulmonary alveolar proteinosis in Azathioprine

Expand to all the drugs that have ingredients of azathioprine sodium:

Pulmonary alveolar proteinosis and drugs with ingredients of azathioprine sodium

Alternative drugs to, pros and cons of Azathioprine:

Azathioprine (59,607 reports)

Common Azathioprine side effects:

Drug ineffective: 8,230 reports
Joint pain: 3,375 reports
Diarrhea: 3,317 reports
Fever: 3,134 reports
Fatigue (feeling of tiredness): 2,780 reports
Rashes (redness): 2,667 reports
Crohn's disease (condition that causes inflammation of the gastrointestinal tract): 2,554 reports

Browse all side effects of Azathioprine:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Pulmonary alveolar proteinosis treatments and more:

Pulmonary alveolar proteinosis (535 reports)

COVID vaccines that are related to Pulmonary alveolar proteinosis:

Common drugs associated with Pulmonary alveolar proteinosis:

Prednisolone: 145 reports

All the drugs that are associated with Pulmonary alveolar proteinosis:

Pulmonary alveolar proteinosis (243 drugs)

All the conditions that are associated with Pulmonary alveolar proteinosis:

Pulmonary alveolar proteinosis (146 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on azathioprine sodium (the active ingredients of Azathioprine) and Azathioprine (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.